Article successfully added.

CyFlow™ CD25 PE-Cy7

CyFlow™ CD25 PE-Cy7
Alternative Name: IL2Rα , p55, TAC
Antibody: Yes
Antigen: CD25
Application: Flow cytometry
Clonality: monoclonal
Clone: MEM-181
Emission Maximum: 785 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: PE-Cy7
Isotype: IgG1
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BM796015

For Research Use Only

$285.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
HLDA Workshop HLDA VI—WS Code NL N-L024 Quantity 100 tests Volume 0.4 mL Immunogen... more
Close menu
CyFlow™ CD25 PE-Cy7
HLDA WorkshopHLDA VI—WS Code NL N-L024
Quantity100 tests
Volume0.4 mL
ImmunogenPHA-activated peripheral blood leucocytes
Background InformationCD25 (IL2Rα, Tac) is a ligand-binding α subunit of interleukin 2 receptor (IL2R). Together with β and γ subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T‑lymphocytes in vitro. Pathology. 1991 Jul; 23(3):224‑8. < PMID: 1838146 > | Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin‑2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan; 143(1):33‑7. < PMID: 1565844 > | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov; 59(Suppl 1):i109‑14. < PMID: 11053100 > | Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct; 28(10):1319‑25. < PMID: 15371947 > | Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May; 19(5):675‑84. < PMID: 17446208 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet